Scinai Immunotherapeutics Investor Relations Material

Scinai Immunotherapeutics Ltd., formerly known as BiondVax Pharmaceuticals Ltd., is an Israeli biopharmaceutical company primarily engaged in the development, manufacture, and commercialization of innovative biological products. The company's focus is on inflammation and immunology, with a particular emphasis on autoimmune and infectious diseases. Scinai's product development pipeline includes a range of nanosized antibodies, known as NanoAbs, derived from alpacas. These antibodies target various diseases with significant unmet medical needs. Additionally, Scinai operates a boutique contract development and manufacturing organization (CDMO) that provides comprehensive services to pharmaceutical, biotech, and alternative protein food tech companies. The company is headquartered in Jerusalem, Israel, and its shares are listed on the NASDAQ.